Executive Series: Virtus Health (VRT) CEO, Sue Channon
In this short video we discuss VRTs’ full year results, which saw NPAT attributable to ordinary equity holders down 14.6% to $28.1m and included a final dividend 12 cents per share fully franked; VRT’s position in the domestic market where it remains the overall leader with 42.1% share of the Australian eastern states market; The importance of VRT’s diagnostic business where revenue increased by nearly 9% in FY17, delivering an EBITDA improvement over the prior year of 37% driven by the new applications of genetic testing and screening in reproductive medicine.
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
1 stock mentioned
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
No areas of expertise
Please sign in to comment on this wire.